HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
1(2H-Phthalazinon-hydrazon
c5968 · ba5968 · c-5068 · apressin · ciba5968 · apresolin · aprezolin · NSC 126699
Identifikatoren & physikalische Daten
| CAS No. | 86-54-4 |
|---|---|
| Summenformel | C8H8N4 |
| Durchschnittliche Molmasse | 160,18 g/mol |
| Monoisotopische Masse | 160,07489626 g/mol |
| SMILES | NNc1nncc2ccccc12 |
| InChIKey | RPTUSVTUFVMDQK-UHFFFAOYSA-N |
| PubChem CID | 3637 |
| ChEMBL | CHEMBL276832 |
| ChEBI | CHEBI:5775 |
| EC No. | 201-680-3 |
| DTXSID | DTXSID4023129 |
| Lokaler Name | 1(2H-Phthalazinon-hydrazon |
Chemische & physikalische Eigenschaften
| XLogP | 0,7 |
|---|---|
| Polarare Oberfläche (TPSA) | 63,8 |
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 4 |
| Frei drehbare Bindungen | 1 |
| Schwere Atome | 12 |
| Formalladung | 0 |
| Komplexität | 150 |
| Stoffklassen | Other Uses -> Pharmaceuticals |
| Arzneimittel | PharmaceuticalsPharmaceuticals -> Listed in ZINC15 |
| LogP (Verteilungskoeffizient) | 0.71.0 |
| Löslichkeit | <1mg/mL2.61e+00 g/L4.8mg/L(22.5 ºC) |
| Human Drugs | Breast FeedingLactationMilk, HumanAntihypertensive AgentsVasodilator AgentsPharmaceuticalsAntihypertensive medicines |
| Schmelzpunkt | 172-173 °C172 - 173 °C172°C |
| Physical Description | Solid |
| Dissociation Constants | 7.3 |
| Collision Cross Section | 132.1 Ų [M+Na]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
| Siedepunkt | 276.07°C (rough estimate) |
| Dichte | 1.2583 (rough estimate) |
| Brechungsindex | 1.5872 (estimate) |
| pKa (Säurekonstante) | pKa 6.820± 0.005(H2O,t = 25.0,Iundefined) (Uncertain) |
| Aggregatzustand | powder |
| BCS Class | 3 |
| InChI | 1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12) |
| InChIKey | RPTUSVTUFVMDQK-UHFFFAOYSA-N |
| SMILES | NNC1=C(C=CC=C2)C2=CN=N1 |
| CAS Datenbank | 86-54-4 |
| NIST chemische Informationen | 1(2H)-phthalazinone, hydrazone(86-54-4) |
| EPA chemische Informationen | Hydralazine (86-54-4) |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.H317: May cause an allergic skin reaction [Warning Sensitization, Skin] |
|---|---|
| Gefahrenübersicht | Asthma and allergic contact dermatitis reported in pharmaceutical workers[Malo] A skin sensitizer in the pharmaceutical industryPatients often have cross-sensitivity with hydrazine[Kanerva, p. 1155] |
| Hazard Classes and Categories | Acute Tox. 3 (100%)Skin sensitization - Category 1 |
| Hepatotoxicity | Serum aminotransferase elevations during hydralazine therapy are considered uncommon. However, hydralazine has been clearly linked to cases of acute liver injury with jaundice as well as a delayed lupus-like syndrome. Two clinical patterns of hepatic injury have been described, associated with either a short (2 to 6 weeks) or long (2 months to more than a year) latency period. The clinically apparent liver injury is usually hepatocellular, although cholestatic forms have also been reported (Case 1). In cases with a short latency period, rash, fever and eosinophilia are common and the onset is typically abrupt and severe, and recovery is rapid. In cases with a longer latency (Case 2), the onset is more typically insidious, liver biopsy may resemble chronic hepatitis and demonstrate fibrosis, and autoantibodies are often present. The late form of hepatitis may also accompany the lupus-like syndrome that occurs with hydralazine, particularly in high doses when given for 6 months or more. Recovery can be prolonged. Autoantibodies to isoforms of the P450 system (CYP 1A2) have been identified in patients with hepatotoxicity due to the structurally related antihypertensive agent dihydralazine (available in Europe, but not the United States) and which is associated with a higher rate of hepatotoxicity than hydralazine. |
| Unerwünschte Wirkungen | Skin Sensitizer - An agent that can induce an allergic reaction in the skin.Hydralazine has been reported to cause headaches, nausea, flushing, hypotension, palpitations, tachycardia, dizziness, and angina. |
| Toxizitätsübersicht | Published reports of toxicity with acute use of hydralazine are uncommon. Signs of toxicity include hypotension, tachycardia, headaches, and generalized flushing. Chronic toxicity could lead to DILE. There is no specific treatment for an overdose other than supportive therapy. Fluids should be given initially, followed by vasopressors if hypotension persists despite fluid resuscitation. Tachycardia or ischemia can be treated with beta-blockers with attention to blood pressure prior to administration. |
| Carcinogen Classification | HydralazineGroup 3: Not classifiable as to its carcinogenicity to humansVolume 24: (1980) Some Pharmaceutical Drugs1987 |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)hydralazineDILI PositiveOralDOI:10.1016/j.drudis.2019.09.022 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| Toxizität | LD50 in mice, rats (mg/kg): 122, 90 orally101, 40 i.p. (Dorigotti) |
| Lagerklasse | 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects |
| Gefahrenklasse | Acute Tox. 3 Oral |
Anwendungen & Verwendung
Beschreibung
Cross-reactions between hydrazine derivatives occur. Hydralazine may sometimes cause flushing and reversible Lupus erythematosis
Verwenden
Hydralazine is a non-nucleoside analog that inhibits DNA methylation and reactivates the expression of tumor suppressor genes. Non-selective MAO-A/B inhibitor; semicarbazide-sensitive amine oxidase inhibitor. Antihypertensive.